1. Charles NS，John S.Resolution of inflammation：the beginning programs the end.Nature Immunology，2005，6（12）：1191-1197.

2. Angus DC，van der Poll，T.Severe Sepsis and Septic Shock.N Engl J Med，2013，369（9）：840-851.

3. Melamed A，Sorvillo FJ.The burden of sepsis-associated mortality in the United States from 1999 to 2005：an analysis of multiple-cause-of-death data.Crit Care，2009，13：R28.

4. Lagu T，Rothberg MB，Shieh MS，et al. Hospitalizations，costs，and outcomes of severe sepsis in the United States 2003 to 2007.Crit Care Med，2012，40：754-756.［Erratum，Crit Care Med 2012，40：2932.］

5. Das UN.Can sepsis and other critical illnesses be predicted and prognosticated？Adv Sepsis，2006，5：52-59.

6. Kinasewitz GT，Yan BS，Basson B，et al.For the PROWESS Sepsis Study Group.Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis，regardless of causative micro-organism［ISRCTN74215569］. Crit Care，2004，8：R82-90.

7. Karlsson S，Pettilä V，Tenhunen J，et al.HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis.Intensive Care Med，2008，34：1046-1053.

8. Yang H，Ochani M，Li J，et al.Reversing established sepsis with antagonists of endogenous high mobility group box-1. Proc Natl Acad Sci USA，2004，101：296-301.

9. Sunden-Cullberg J，Norrby-Teglund A，Rouhiainen A，et al. Persistent elevation of high mobility group box-1 protein （HMGB1）in patients with severe sepsis and septic shock. Crit Care Med，2005，33：564-573.

10. Felmet KA，Hall MW，Clark RS，et al.Prolonged lymphopenia，lymphoid depletion，and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure.J Immunol，2005，174：3765-3772.

11. Arbour NC，Lorenz E，Schutte BC，et al.TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet，2000，25：187-191.

12. Das UN.Critical advances in septicemia and septic shock. Crit Care，2000，4：290-294.

13. Shishido T，Nozaki N，Takahashi H，et al.Central role of endogenous toll-like receptor-2 activation in regulating inflammation，reactive oxygen species production，and subsequent neointimal formation after vascular injury.Biochem Biophys Res Commun，2006，345：1446-1453.

14. Norris PC，Reichart D，Dumlao DS，et al.Specificity of eicosanoid production depends on the TLR-four-stimulated macrophage phenotype.J Leukoc Biol，2011，90：563-574.

15. Lefebvre JS，Marleau S，Milot V，et al.Toll-like receptor ligands induce polymorphonuclear leukocyte migration：key roles for leukotriene B4 and platelet-activating factor. FASEB J，2010，24：637-647.

16. Ruipérez V，Astudillo AM，Balboa MA，et al.Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A2s.J Immunol，2009，182：3877-3883.

17. Font-Nieves M，Sans-Fons MG，Gorina R，et al.Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide（LPS）control prostaglandin E2 production in astrocytes.J Biol Chem，2012，287：6454-6468.

18. Gorina R，Font-Nieves M，Márquez-Kisinousky L，et al.Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NF-κB signaling，MAPK，and Jak1/Stat1 pathways.Glia，2011，59：242-255.

19. Lu J，Jilling T，Li D，et al.Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model.Pediatr Res，2007，61：427-432.

20. Hassan IR，Gronert K. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1.J Immunol，2009，182：3223-3232.

21. Ueda T.Fukunaga K.Seki H，et al.Combination Therapy of 15-Epi-Lipoxin A4 With Antibiotics Protects Mice From Escherichia coli-Induced Sepsis.Crit Care，Med 2014.

22. Eisen DP.Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis. Intensive Care Med，2012.

23. Hennekens CH，Schneider WR，Pokov A，et al.A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.J Cardiovasc Pharmacol Ther，2010，15：344-348.

24. Eisen DP，Reid D，McBryde ES.Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis.Crit Care Med，2012，40（6）：1761-1767.

25. Spite M，Norling LV，Summers L，et al.Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature，2009，461：1287-92.

26. Bitto A，Minutoli L，David A，et al.Flavocoxid，a dual inhibitor of COX-2 and 5-LOX of natural origin，attenuates the inflammatory response and protects mice from sepsis. Crit Care，2012，16：R32.

27. Lawrence T，Gilroy DW.Chronic inflammation：a failure of resolution？Int J Exp Pathol，2007，88（2）：85-94.

28. Gilroy DW，Lawrence T，Perretti M，et al.Inflammatory resolution：new opportunities for drug discovery.Nat Rev Drug Discov，2004，3（5）：401-416.

29. Maldonado-Pérez D，Golightly E，Denison FC，et al.A role for lipoxin A ₄as anti-inflammatory and proresolution mediator in human parturition.FASEB J，2011，25（2）：569-575.

30. Maderna P，Godson C.Mediators and receptors in the resolution of inflammation.Review，Lipoxins：resolutionary road. British Journal of Pharmacology，2009，158：947-959.

31. Jin S，Zhang L，Lian Q，et al.Post-treatment with aspirintriggered lipoxin A4 analog attenuates lipopolysaccharide induced acute lung injury in mice.the role of hemeoxygenase-1.Anesth Analg，2007，104：369-77.

32. Walker J，Dichter E，Lacorte G，et al.Lipoxin A4 increases survival by decreasing systemic inflammation and bacterial load in sepsis.Shock，2011，36：410-416.

33. Norling LV，Spite M，Yang R，et al.Cutting edge：humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing.J Immunol，2011，186：5543-5547.

34. Das UN.Influence of polyunsaturated fatty acids and their metabolites on stem cell biology.Nutrition，2011，27：21-25.

35. Das UN.Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation，cancer，and metastasis. Cancer Metastasis Rev，2011，30：311-324.